Scalable Success: Electronic Patient-Managed Interventions Significantly Drive Benzodiazepine Cessation
Posted innews Psychiatry Public Health

Scalable Success: Electronic Patient-Managed Interventions Significantly Drive Benzodiazepine Cessation

The EMPOWER-ED randomized clinical trial demonstrates that an electronic, patient-centered intervention significantly increases the odds of complete benzodiazepine cessation among long-term users, providing a scalable, low-cost solution for health systems to address benzodiazepine dependence without increasing clinician burden.
Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders
Posted inNeurology news Orthopedics

Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders

The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the intervention is broadly applicable regardless of baseline psychological or physical factors.
Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial
Posted inDiabetes & Endocrinology news

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering a safe intervention for a long-standing clinical challenge.
Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?
Posted inCardiology Internal Medicine news

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest a potential clinical benefit in treatment intensification and family communication.
Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1
Posted inHematology-Oncology news

Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1

The EPCORE CLL-1 trial evaluated epcoritamab, a CD3×CD20 bispecific antibody, in patients with Richter transformation. While the 47.6% overall response rate narrowly missed the 50% target, the results highlight a significant therapeutic signal in a population with historically poor outcomes and high-risk genetic features.
High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial
Posted inAnesthesiology news Respiratory

High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial

The international PROTHOR trial reveals that using higher PEEP and recruitment manoeuvres during one-lung ventilation does not decrease postoperative pulmonary complications compared to a lower PEEP strategy, while notably increasing intraoperative hemodynamic risks like hypotension and arrhythmias.
Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study
Posted inHematology-Oncology news

Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study

The phase 2 ICON trial reveals that iberdomide combined with low-dose cyclophosphamide and dexamethasone (IberCd) achieves a median PFS of 17.6 months in lenalidomide-refractory multiple myeloma. This all-oral regimen represents a significant advancement in convenience and efficacy for heavily pretreated patients.
Prostate Cancer Statistics 2025: The Resurgence of Advanced Disease and Persistent Racial Disparities
Posted inClinical Updates news Oncology

Prostate Cancer Statistics 2025: The Resurgence of Advanced Disease and Persistent Racial Disparities

This review analyzes 2025 prostate cancer data, highlighting a 3% annual incidence increase primarily driven by advanced-stage disease. It explores age-specific trends, significant racial inequities in mortality, and the clinical challenges of optimizing early detection while managing advanced disease complications.
Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial
Posted innews Oncology Otorhinolaryngology

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction in long-term toxicities such as gastrostomy tube dependence.